Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Viralytics Ltd. (OTC: VRACY).

Full DD Report for VRACY

You must become a subscriber to view this report.

Recent News from (OTC: VRACY)

Wall Street Breakfast: Investors Brace For Fed Minutes
The Fed is set to release the minutes from its last gathering in January, which could have more impact than usual if they provide new insight on inflation or interest rates. Fears of rising inflation are at the heart of what's recently been ailing the stock market. The minutes coul...
Source: SeekingAlpha
Date: February, 21 2018 06:37
Merck to buy Viralytics for $394M
Already one of the leaders in the hot area of cancer immunotherapy, Merck & Co (NYSE: MRK ) has agreed to buy Viralytics ( OTCQX:VRACY ) for A$502M ($394M) to expand its drug pipeline. More news on: Merck & Co Inc., Viralytics Ltd. ADR, Viralytics Ltd., Merger & acquisition n...
Source: SeekingAlpha
Date: February, 21 2018 05:34
Merck and Viralytics Announce Acquisition Agreement, Expanding Merck's Leading Immuno-Oncology Pipeline
Proposed Acquisition of Viralytics Would Add Investigational Oncolytic Immunotherapy, CAVATAK ® , Supporting Merck’s Strategy to Broaden Its Pipeline with the Best Scientific Assets Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Viralytics Li...
Source: Business Wire
Date: February, 21 2018 04:00
Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug
Deals and Financings Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase ...
Source: SeekingAlpha
Date: January, 14 2018 07:19


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VRACY.

About Viralytics Ltd. (OTC: VRACY)

Logo for Viralytics Ltd. (OTC: VRACY)

lt p gt Viralytics Limited, a biotechnology company, engages in the development of oncolytic virotherapy for the treatment of a range of cancers. lt /p gt




Current Management

  • Malcolm McColl / CEO, Managing Director
  • Robert Vickery / CFO
  • Sarah Prince / Secretary
  • Darren Shafren / Chief Scientific Officer
  • Jennifer Dinneen / Accountant
  • Paul Hopper / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Leonard Post / NonExecutive Director, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Peter Turvey / NonExecutive Director

Current Share Structure

  • Market Cap: $317,623,353 - 03/12/2018
  • Authorized: 240,623,752 - 05/14/2017
  • Issue and Outstanding: 240,623,752 - 05/14/2017


Recent Filings from (OTC: VRACY)

Semi-Annual Report - Appendix 4D Half Yearly Report and Accounts
Filing Type: Semi-Annual Report - Appendix 4D Half Yearly Report and AccountsFiling Source: OTC Markets
Filing Date: February, 26 2018
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: January, 31 2018
Quarterly Report - Appendix 4C - quarterly
Filing Type: Quarterly Report - Appendix 4C - quarterlyFiling Source: OTC Markets
Filing Date: October, 25 2017



Daily Technical Chart for (OTC: VRACY)

Daily Technical Chart for (OTC: VRACY)

Stay tuned for daily updates and more on (OTC: VRACY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: VRACY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VRACY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VRACY and does not buy, sell, or trade any shares of VRACY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: